Advances in Chronic Kidney Disease
Volume 14, Issue 1 , Pages 54-66 , January 2007

Mechanisms of Vascular Calcification

References 

  1. London GM, Marchais SJ, Guerin AP, et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens. 2005;14:525–531
  2. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95:560–567
  3. London GM. Cardiovascular calcifications in uremic patients: Clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14:S305–S309
  4. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31:607–617
  5. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  6. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179–1187
  7. Shigematsu T, Kono T, Satoh K, et al. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Transplant. 2003;18:iii86–iii89
  8. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  9. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  10. Chertow GM, Raggi P, McCarthy JT, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol. 2003;23:307–314
  11. Raggi P, Ali O. Phosphorus restriction and control of coronary calcification as assessed by electron beam tomography. Curr Opin Nephrol Hypertens. 2002;11:391–395
  12. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–1154
  13. Chen NX, O’Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724–1731
  14. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–E17
  15. Shioi A, Nishizawa Y, Jono S, et al. Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995;15:2003–2009
  16. Mizobuchi M, Ogata H, Hatamura I, et al. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol Dial Transplant. 2006;21:911–916
  17. Tyson KL, Reynolds JL, McNair R, et al. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23:489–494
  18. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res. 2006;98:905–912
  19. Harmey D, Hessle L, Narisawa S, et al. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: An integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164:1199–1209
  20. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation (A possible explanation for the paradox of arterial calcification in osteoporotic patients). Arterioscler Thromb Vasc Biol. 1997;17:680–687
  21. Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000;102:2636–2642
  22. Fleisch H, Bisaz S. Mechanism of calcification: Inhibitory role of pyrophosphate. Nature. 1962;195:911
  23. Terkeltaub RA. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol. 2001;281:C1–C11
  24. Johnson K, Polewski M, van Etten D, et al. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol. 2005;25:686–691
  25. Towler DA. Inorganic pyrophosphate: A paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol. 2005;25:651–654
  26. Lomashvili KA, Khawandi W, O’Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005;16:2495–2500
  27. Wendling D, Jeannin-Louys L, Kremer P, et al. Adult hypophosphatasia (Current aspects). Joint Bone Spine. 2001;68:120–124
  28. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet. 2003;34:379–381
  29. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003;18:994–1004
  30. Klemmer PJ. Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients. Blood Purif. 2005;23:12–19
  31. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20:1653–1661
  32. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol. 2003;14:S310–S314
  33. Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate–phosphorus metabolism and cardiovascular calcification. Clin Nephrol. 2004;62:104–115
  34. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  35. Pai AB, Smeeding JE, Brook RA. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia. Curr Med Res Opin. 2004;20:991–999
  36. Haffner D, Hocher B, Muller D, et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens. 2005;23:1067–1075
  37. Kerr DN. Hypercalcemia and metastatic calcification. Cardiovasc Res. 1997;36:293–297
  38. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66:2293–2299
  39. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857–2867
  40. Gonzalez EA, Sachdeva A, Oliver DA, et al. Vitamin D insufficiency and deficiency in chronic kidney disease (A single center observational study). Am J Nephrol. 2004;24:503–510
  41. Reichel H, Deibert B, Schmidt-Gayk H, et al. Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant. 1991;6:162–169
  42. Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant. 2002;17:723–731
  43. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant. 2003;18:iii2–iii28
  44. Lopez I, Aguilera-Tejero E, Mendoza FJ, et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol. 2006;17:795–804
  45. Tamura K, Suzuki Y, Hashiba H, et al. Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy. J Pharmacol Sci. 2005;99:89–94
  46. Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant. 2003;18:1770–1776
  47. Wu-Wong JR, Nakane M, Traylor L, et al. Cardiovascular disease in chronic kidney failure: the role of VDR activators. Curr Opin Investig Drugs. 2006;7:206–213
  48. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456
  49. Shioi A, Katagi M, Okuno Y, et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: Roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res. 2002;91:9–16
  50. Jono S, Nishizawa Y, Shioi A, et al. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98:1302–1306
  51. Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005;18:307–314
  52. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–S19
  53. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002;106:100–105
  54. Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant. 2006;21:2464–2471
  55. Tamagaki K, Yuan Q, Ohkawa H, et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrol Dial Transplant. 2006;21:651–659
  56. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394–401
  57. Ahmed S, O’Neill KD, Hood AF, et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. 2001;37:1267–1276
  58. Duffy A, Schurr M, Warner T, et al. Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol. 2006;13:96–102
  59. Shao JS, Cheng SL, Charlton-Kachigian N, et al. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003;278:50195–50202
  60. Jono S, Nishizawa Y, Shioi A, et al. Parathyroid hormone-related peptide as a local regulator of vascular calcification (Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells). Arterioscler Thromb Vasc Biol. 1997;17:1135–1142
  61. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435
  62. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–568
  63. Benet-Pages A, Orlik P, Strom TM, et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005;14:385–390
  64. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421–432
  65. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51
  66. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281:6120–6123
  67. Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279
  68. Pande S, Ritter CS, Rothstein M, et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104:23–32
  69. Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF23 in CKD. Nephrol Dial Transplant. 2005;20:1295–1298
  70. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943–1951
  71. Hak AE, Pols HA, van Hemert AM, et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000;20:1926–1931
  72. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep. 2003;3:28–32
  73. Parving HOR, Ritz E. Diabetic nephropathy. In:  Brenner S editors. The Kidney. Philadelphia, PA: Saunders; 2000;p. 1731
  74. Cheng SL, Shao JS, Charlton-Kachigian N, et al. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem. 2003;278:45969–45977
  75. Shao JS, Cheng SL, Pingsterhaus JM, et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210–1220
  76. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: Lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006;26:1423–1430
  77. Bostrom K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800–1809
  78. Shanahan CM, Cary NR, Metcalfe JC, et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:2393–2402
  79. Jono S, Nishizawa Y. [Measurement of serum MGP] Clin Calcium. 2002;12:1102–1104
  80. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67:2295–2304
  81. Spronk HM, Soute BA, Schurgers LJ, et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun. 2001;289:485–490
  82. Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regulating proteins in association with Monckeberg’s sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100:2168–2176
  83. Mori K, Shioi A, Jono S, et al. Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett. 1998;433:19–22
  84. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81
  85. Hur DJ, Raymond GV, Kahler SG, et al. A novel MGP mutation in a consanguineous family: Review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A. 2005;135:36–40
  86. Murshed M, Schinke T, McKee MD, et al. Extracellular matrix mineralization is regulated locally: Different roles of two gla-containing proteins. J Cell Biol. 2004;165:625–630
  87. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400–1407
  88. Moe SM, Chen NX. Calciphylaxis and vascular calcification: A continuum of extra-skeletal osteogenesis. Pediatr Nephrol. 2003;18:969–975
  89. Schurgers LJ, Teunissen KJ, Knapen MH, et al. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol. 2005;25:1629–1633
  90. Jono S, Ikari Y, Vermeer C, et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost. 2004;91:790–794
  91. Schurgers LJ, Teunissen KJ, Knapen MH, et al. Characteristics and performance of an immunosorbent assay for human matrix Gla-protein. Clin Chim Acta. 2005;351:131–138
  92. Price PA, Caputo JM, Williamson M. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: Biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res. 2002;17:1171–1179
  93. Zebboudj AF, Imura M, Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277:4388–4394
  94. Farzaneh-Far A, Davies JD, Braam LA, et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem. 2001;276:32466–32473
  95. Spronk HM. Vitamin K epoxide reductase complex and vascular calcification: Is this the important link between vitamin K and the arterial vessel wall?. Circulation. 2006;113:1550–1552
  96. Gopalakrishnan R, Suttamanatwong S, Carlson AE, et al. Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. Cells Tissues Organs. 2005;181:166–175
  97. Farzaneh-Far A, Proudfoot D, Weissberg PL, et al. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun. 2000;277:736–740
  98. Farzaneh-Far A, Weissberg PL, Proudfoot D, et al. Transcriptional regulation of matrix gla protein. Z Kardiol. 2001;90:38–42
  99. Schinke T, Amendt C, Trindl A, et al. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells (A possible role in mineralization and calcium homeostasis). J Biol Chem. 1996;271:20789–20796
  100. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet. 2003;361:827–833
  101. Odamaki M, Shibata T, Takita T, et al. Serum fetuin-A and aortic calcification in hemodialysis patients. Kidney Int. 2005;68:2915
  102. Coen G, Manni M, Agnoli A, et al. Cardiac calcifications: Fetuin-A and other risk factors in hemodialysis patients. ASAIO J. 2006;52:150–156
  103. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int. 2005;67:1070–1077
  104. Ix JH, Chertow GM, Shlipak MG, et al. Fetuin-A and kidney function in persons with coronary artery disease—Data from the heart and soul study. Nephrol Dial Transplant. 2006;21:2144–2151
  105. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int. 2005;67:2383–2392
  106. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357–366
  107. Hendig D, Schulz V, Arndt M, et al. Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem. 2006;52:227–234
  108. Jahnen-Dechent W, Schafer C, Heiss A, et al. Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin. Z Kardiol. 2001;90:47–56
  109. Price PA, Thomas GR, Pardini AW, et al. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem. 2002;277:3926–3934
  110. Demetriou M, Binkert C, Sukhu B, et al. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem. 1996;271:12755–12761
  111. Binkert C, Demetriou M, Sukhu B, et al. Regulation of osteogenesis by fetuin. J Biol Chem. 1999;274:28514–28520
  112. Mathews ST, Chellam N, Srinivas PR, et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. 2000;164:87–98
  113. Nakamura O, Kazi JA, Ohnishi T, et al. Effects of rat fetuin on stimulation of bone resorption in the presence of parathyroid hormone. Biosci Biotechnol Biochem. 1999;63:1383–1391
  114. Jahnen-Dechent W, Trindl A, Godovac-Zimmermann J, et al. Posttranslational processing of human alpha 2-HS glycoprotein (human fetuin) (Evidence for the production of a phosphorylated single-chain form by hepatoma cells). Eur J Biochem. 1994;226:59–69
  115. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res. 2005;97:105–114
  116. Davies MR, Lund RJ, Hruska KA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol. 2003;14:1559–1567
  117. Hruska KA, Mathew S, Davies MR, et al. Connections between vascular calcification and progression of chronic kidney disease: Therapeutic alternatives. Kidney Int Suppl. 2005;99:S142–S151
  118. Dorai H, Sampath TK. Bone morphogenetic protein-7 modulates genes that maintain the vascular smooth muscle cell phenotype in culture. J Bone Joint Surg Am. 2001;83A:S70–S78
  119. Hruska KA, Saab G, Chaudhary LR, et al. Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. Semin Nephrol. 2004;24:25–38
  120. Steidl L, Ditmar R. Treatment of soft tissue calcifications with magnesium. Acta Univ Palacki Olomuc Fac Med. 1991;130:273–287
  121. Schmiedl A, Schmiedl PO, Bonucci E, et al. Renal cortical calcification in syngeneic intact rats and those receiving an infrarenal thoracic aortic graft: Possible etiological roles of endothelin, nitrate and minerals, and different preventive effects of long-term oral treatment with magnesium, citrate and alkali-containing preparations. Urol Res. 2001;29:229–237
  122. Goulding A, Malthus RS. Effect of dietary magnesium on the development of nephrocalcinosis in rats. J Nutr. 1969;97:353–358
  123. Izawa H, Imura M, Kuroda M, et al. Proceedings: Effect of magnesium on secondary hyperparathyroidism in chronic hemodialysis: A case with soft tissue calcification improved by high Mg dialysate. Calcif Tissue Res. 1974;15:162
  124. Leonard F, Boke JW, Ruderman RJ, et al. Initiation and inhibition of subcutaneous calcification. Calcif Tissue Res. 1972;10:269–279
  125. Levine BS, Coburn JW. Magnesium, the mimic/antagonist to calcium. N Engl J Med. 1984;310:1253–1255
  126. Gupta LC, Singla SK, Tandon C, et al. Mg2+: A potent inhibitor of collagen-induced in vitro mineralization. Magnes Res. 2004;17:67–71
  127. Bachra BN, Fischer HR. The effect of some inhibitors on the nucleation and crystal growth of apatite. Calcif Tissue Res. 1969;3:348–357
  128. Inagaki O, Syono T, Nakagawa K, et al. Influence of magnesium deficiency on concentration of calcium in soft tissue of uremic rats. Ren Fail. 1996;18:847–854
  129. Schwille PO, Schmiedl A, Schwille R, et al. Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat—Differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali. Biomed Pharmacother. 2003;57:88–97
  130. Ito M, Cho BH, Kummerow FA. Effects of a dietary magnesium deficiency and excess vitamin D3 on swine coronary arteries. J Am Coll Nutr. 1990;9:155–163
  131. Bloom S. Coronary arterial lesions in Mg-deficient hamsters. Magnesium. 1985;4:82–95
  132. Rayssiguier Y. Role of magnesium and potassium in the pathogenesis of arteriosclerosis. Magnesium. 1984;3:226–238
  133. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int. 1987;32:388–394
  134. Wei M, Esbaei K, Bargman J, et al. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: A literature review. Perit Dial Int. 2006;26:366–373
  135. Navarro JF, Mora C, Jimenez A, et al. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients. Am J Kidney Dis. 1999;34:43–48
  136. Sherwood LM, Herrman I, Bassett CA. Parathyroid hormone secretion in vitro: Regulation by calcium and magnesium ions. Nature. 1970;225:1056–1058
  137. Ferment O, Garnier PE, Touitou Y. Comparison of the feedback effect of magnesium and calcium on parathyroid hormone secretion in man. J Endocrinol. 1987;113:117–122
  138. Targovnik JH. The effects of calcium and magnesium of PTH secretion. Ariz Med. 1971;28:263
  139. Cholst IN, Steinberg SF, Tropper PJ, et al. The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med. 1984;310:1221–1225
  140. Navarro JF, Mora C, Garcia J. Serum magnesium and parathyroid hormone levels in dialysis patients. Kidney Int. 2000;57:2654
  141. Gohda T, Shou I, Fukui M, et al. Parathyroid hormone gene polymorphism and secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis. 2002;39:1255–1260
  142. McGonigle RJ, Weston MJ, Keenan J, et al. Effect of hypermagnesemia on circulating plasma parathyroid hormone in patients on regular hemodialysis therapy. Magnesium. 1984;3:1–7
  143. Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism: Part I (Physiology). Crit Care Resusc. 2002;4:301–306
  144. Kelber J, Slatopolsky E, Delmez JA. Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis. Am J Kidney Dis. 1994;24:453–460
  145. Shoji T, Ishimura E, Inaba M, et al. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis. 2001;38:S30–S33
  146. Tamashiro M, Iseki K, Sunagawa O, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 2001;38:64–69
  147. Bild DE, Folsom AR, Lowe LP, et al. Prevalence and correlates of coronary calcification in black and white young adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol. 2001;21:852–857
  148. Callister TQ, Raggi P, Cooil B, et al. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972–1978
  149. Towler DA, Bidder M, Latifi T, et al. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 1998;273:30427–30434
  150. Jiang T, Liebman SE, Lucia MS, et al. Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int. 2005;68:2608–2620
  151. Jiang T, Wang Z, Proctor G, et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem. 2005;280:32317–32325
  152. Parhami F, Basseri B, Hwang J, et al. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002;91:570–576
  153. Demer LL, Tintut Y, Parhami F. Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens. 2002;11:437–443
  154. Abedin M, Lim J, Tang TB, et al. N-3 fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-gamma pathways. Circ Res. 2006;98:727–729
  155. Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650–655
  156. Tintut Y, Parhami F, Bostrom K, et al. cAMP stimulates osteoblast-like differentiation of calcifying vascular cells (Potential signaling pathway for vascular calcification). J Biol Chem. 1998;273:7547–7553
  157. Zanos S, Mitsopoulos E, Sakellariou G. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients. Ren Fail. 2005;27:163–169
  158. Llach F. Hyperphosphatemia in end-stage renal disease patients: Pathophysiological consequences. Kidney Int Suppl. 1999;73:S31–S37
  159. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34–38
  160. Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1489–1496
  161. Rutsch F, Schauerte P, Kalhoff H, et al. Low levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a boy with idiopathic infantile arterial calcification. Acta Paediatr. 2000;89:1265–1269
  162. Moe SM. Disorders of calcium, phosphorus, and magnesium. Am J Kidney Dis. 2005;45:213–218
  163. Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005;16:2920–2930
  164. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268
  165. Price PA, June HH, Buckley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610–1616
  166. Nitta K, Akiba T, Uchida K, et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1886–1889
  167. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006;17:262–270
  168. Henley C, Colloton M, Cattley RC, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1370–1377
  169. Mucsi I, Almasi C, Deak G, et al. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol. 2005;64:288–294
  170. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol. 2003;14:159–168
  171. Lomashvili K, Garg P, O’Neill WC. Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int. 2006;69:1464–1470
  172. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37:S54–S57
  173. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927–1932
  174. Rutsch F, Maffert R, Ropers D, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001;158:543–554
  175. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of Klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;280:1015–1020
  176. Wada T, McKee MD, Steitz S, et al. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res. 1999;84:166–178
  177. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: Evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196:1047–1055
  178. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002;161:2035–2046
  179. Ohri R, Speer MY, McKee MD, et al. Mitigation of ectopic calcification in osteopontin-deficient mice by exogenous osteopontin. Calcif Tissue Int. 2005;76:307–315
  180. Moe SM. Uremic vasculopathy. Semin Nephrol. 2004;24:413–416
  181. Moe SM, Duan D, Doehle BP, et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003–1011
  182. Moe SM, O’Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638–647
  183. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998–2003
  184. Chen NX, Duan D, O’Neill KD, et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int. 2006;70:1046–1053
  185. Dorai H, Vukicevic S, Sampath TK. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol. 2000;184:37–45
  186. Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol. 2006;3:151–154

 Supported in part by NIH grants HL62329 and HL081785.

PII: S1548-5595(06)00169-8

doi: 10.1053/j.ackd.2006.10.007

Advances in Chronic Kidney Disease
Volume 14, Issue 1 , Pages 54-66 , January 2007

Article Tools